Preferred Name |
Moexipril |
|
Synonyms |
|
|
Definitions |
A non-sulfhydryl angiotensin converting enzyme (ACE) inhibitor with antihypertensive activity. As a prodrug, moexipril is hydrolyzed into its active form moexiprilat, which competitively inhibits ACE, thereby blocking the conversion of angiotensin I to angiotensin II. This prevents the actions of the potent vasoconstrictor angiotensin II and leads to vasodilation. It also prevents angiotensin II-induced aldosterone secretion by the adrenal cortex, thereby promoting diuresis and natriuresis. |
|
ID |
http://purl.obolibrary.org/obo/NCIT_C83967 |
|
CAS_Registry |
103775-10-6 |
|
Chemical_Formula |
C27H34N2O7 |
|
code |
C83967 |
|
Contributing_Source |
FDA |
|
definition |
A non-sulfhydryl angiotensin converting enzyme (ACE) inhibitor with antihypertensive activity. As a prodrug, moexipril is hydrolyzed into its active form moexiprilat, which competitively inhibits ACE, thereby blocking the conversion of angiotensin I to angiotensin II. This prevents the actions of the potent vasoconstrictor angiotensin II and leads to vasodilation. It also prevents angiotensin II-induced aldosterone secretion by the adrenal cortex, thereby promoting diuresis and natriuresis. |
|
FDA_UNII_Code |
WT87C52TJZ |
|
Has_Salt_Form | ||
in_subset | ||
label |
Moexipril |
|
Preferred_Name |
Moexipril |
|
prefixIRI |
NCIT:C83967 |
|
prefLabel |
Moexipril |
|
Semantic_Type |
Pharmacologic Substance |
|
UMLS_CUI |
C0066685 |
|
subClassOf |